Research report 2026-05-04 – 2026-07-03

The GLP-1 Divide: A Western Fix?

6 min read 6 episodes 3 podcasts 38% cited

Updated 2 weeks, 4 days ago

Photo by taakill on Pexels

By the numbers

US adult uptake
12.4%
vs ~2% EU/UK
Lilly tirzepatide sales
$45B+
2026 projected
Oral Wegovy weight loss
16.6%
mean, 64 weeks
Medicare Bridge copay
$50/mo
from 1 Jul 2026
Overview

Roughly 12.4% of US adults now take a GLP-1 for weight loss, against about 2% across the EU and UK — the same molecule, a sixfold divide. Scott Galloway argues GLP-1s will do more for human lives and shareholder value than AI, and the clinical case keeps widening: beyond weight and diabetes, these drugs appear to slow or reverse fatty liver disease, chronic kidney disease and osteoarthritis, and may cut cardiovascular and stroke risk. But the podcast debate keeps circling a harder question — whether a drug powerful enough to erase alcohol cravings lets us stop addressing the poverty, loneliness and food environment that produced the problem. Access is now policy: the FDA approved the first oral GLP-1 in December 2025, and from 1 July 2026 Medicare offers eligible beneficiaries GLP-1s at $50 a month.

Most represented

Top voices

  • TED Talks Daily 6
  • On Purpose with Jay Shetty 3
  • The Diary Of A CEO with Steven Bartlett 3
  • Elon Musk 18
  • Sam Altman 18
  • Steve Jobs 8
  • Aristotle 5
  • Manoush Zomorodi 5

The arguments

GLP-1s beat AI on human impact

Galloway's claim: measured by lives changed and shareholder value created, the GLP-1 class outweighs the AI boom.

Medicalizing addiction abandons root causes

When a drug works this well, the temptation is to stop fixing poverty, loneliness, trauma and the food environment that generate the disease.

The benefits are genuinely shocking

Effects extend well past weight — fatty liver, kidney disease, osteoarthritis, cardiovascular risk — and some appear independent of weight loss itself.

A bridge, not a shortcut

For patients trapped in a catch-22 — too heavy for the surgery that would save them — the drug is the only route back to the intervention that works.

Mixed verdict

Obesity is metabolic, not moral

If obesity is a protection mechanism against energy the mitochondria cannot process, then willpower framing is a category error — and so is treating the drug as cheating.

The Case That Keeps Growing

Scott Galloway's assessment is blunt: 'if you look at what's really gonna have an impact on people's lives and what will create more shareholder value, I think it's GLP-one than AI'. The clinical evidence is doing the arguing for him. Beyond weight and diabetes, GLP-1s appear to slow or reverse fatty liver disease, chronic kidney disease and osteoarthritis, and may reduce cardiovascular and stroke risk — with some effects appearing independent of weight loss itself.

The pipeline compounds the case. Eli Lilly's retatrutide hits three receptors versus the current drugs' one or two and has completed Phase 3 trials; oral versions are arriving. The first landed on 22 December 2025, when the FDA approved the oral Wegovy pill (semaglutide 25 mg) — 16.6% mean weight loss, with a third of participants losing 20% or more, plus an indication to reduce major adverse cardiovascular events. Novo's franchise is projected at $34.8 billion in 2026 sales, while Lilly's tirzepatide products are forecast above $45 billion — enough to overtake Keytruda as the world's best-selling drug. The obesity-specific segment is the steeper curve: $8.2 billion in 2025, forecast to reach $39.5 billion by 2030 and $65.4 billion by 2035, a 23.1% compound growth rate.

Exhibit 1

Projected 2026 global sales by franchise (US$)

Source [10] · as of 2026-06-16

Exhibit 2

Obesity-specific GLP-1 market projection (US$)

Source [16] · as of 2025-10-14

Major GLP-1 manufacturers

Mary, and the Question Underneath

Mary had tried rehab, AA and Antabuse, and failed every time. She enrolled in a clinical trial for Ozempic, and within weeks the craving was simply gone. She stopped drinking and lost 55 pounds in five months — eventually having to stop the drug because of excessive weight loss, though she kept her sobriety. The 'alcohol noise' that had organized her life went quiet, not through insight or willpower, but through a receptor.

This is where Dhruv Khullar locates the discomfort. When a drug is powerful enough, it becomes tempting to stop addressing the social root causes — poverty, loneliness, trauma, the food environment — that produce the problem in the first place. The counterargument sits in the same lecture: years before Ozempic existed, Khullar cared for a taxi driver who needed heart surgery but was too heavy to safely operate on. The surgeon said lose weight and come back; everyone knew that was impossible. For that patient the drug is not a shortcut around the hard work — it is the only bridge to the intervention that saves his life.

The Divide Is the Price

The same molecule produces radically different societies. Around 12.4% of US adults report taking a GLP-1 for weight loss, against roughly 2% across the EU and UK. That gap is not appetite; it is a price. Americans pay two to four times what their European peers pay — European monthly out-of-pocket costs run $83 to $144, while US self-pay sits between $150 and $450 even after recent cuts. In September 2025 Eli Lilly pushed a UK list price increase of up to 170% for privately purchased Mounjaro, exporting American pricing into the European private market.

Policy is now doing what negotiation didn't. The Trump administration's November 2025 Most Favored Nation deal anchored consumer prices for self-pay injectables at roughly $350 a month, and CMS launched the Medicare GLP-1 Bridge on 1 July 2026: eligible Part D beneficiaries pay $50 a month for Wegovy, Zepbound's KwikPen and the Foundayo pill, running through 31 December 2027. Roughly 3.8 million beneficiaries may be eligible — but the copay does not count toward the Part D deductible or the out-of-pocket cap, which is the sort of detail that decides whether access is real.

Exhibit 3

GLP-1 adult uptake vs typical monthly out-of-pocket cost

Source [11] · as of 2026-02-04

Monthly out-of-pocket patient costs (2026)
Payer / region Monthly cost (US$)
United States (self-pay) $150 – $450
United States (MFN reference) ~$350
United States (Medicare GLP-1 Bridge) $50
Europe (general range) $83 – $144

Source [11] · as of 2026-02-04

Pricing and regulatory milestones

Eli Lilly raises the private UK list price of Mounjaro by up to 170%.

The administration anchors US self-pay injectable prices around $350 per month.

FDA approves the Wegovy pill (oral semaglutide 25 mg) for weight management.

Novo Nordisk begins the US commercial rollout of oral Wegovy.

Eligible Part D beneficiaries pay $50/month through December 2027; ~3.8 million may qualify.

Source [15] · as of 2026-07-01

What the Drug Doesn't Fix

The mechanism story is being rewritten in a way that undercuts the moral framing on both sides. Dr Martin Picard describes obesity as 'a protection mechanism against excess energy resistance' — too much energy in the system, mitochondria that cannot keep up, cells protecting themselves. Chris Palmer extends the logic: decades of converging neuroscience point to metabolic dysfunction, not just genes or trauma, as a root driver of conditions from depression to schizophrenia. If obesity and mental illness share a metabolic root, then a drug acting on that root is neither cheating nor a cure — it is one lever among several.

Costs surface where the trials didn't look. A survey of 1,000 women who had taken GLP-1 weight-loss drugs found roughly 25% reported sexual side effects. And the environment the drug is dropped into remains untreated: Nicholas Christakis's Yale work found obesity, happiness, loneliness and smoking propagate through three degrees of social connection — your friends' friends shape you. A prescription reaches one body; the network that produced the outcome stays intact.

Open questions

Angles still unanswered — threads worth pursuing.

  1. If GLP-1s blunt alcohol, nicotine and gambling cravings alike, what exactly are we treating — appetite, or the reward system itself?

    Mary's alcohol noise vanished on a weight-loss drug; the addiction field has no framework for a molecule that treats a category rather than a substance.

  2. Does the Medicare Bridge's exclusion of the $50 copay from the out-of-pocket cap quietly recreate the access gap it was built to close?

    A copay that never counts toward the deductible or the Part D cap is a permanent tax on the sickest beneficiaries.

  3. Why is a sixfold uptake divide between the US and Europe treated as a pricing artefact rather than a natural experiment?

    Two comparable populations, the same molecule, radically different exposure — the long-run outcome data will be the most valuable evidence in the field, and nobody is designed to collect it.

  4. If obesity is mitochondrial protection against energy the system cannot process, does suppressing intake treat the cause or the symptom?

    The metabolic model implies the food environment is the disease and the drug is the bandage — precisely the root-cause abandonment Khullar warns about.

References

  1. The Diary Of A CEO with Steven Bartlett Scott Galloway: AI Wasn’t Built For You. The Rich Don’t Need You Anymore! — Scott Galloway “I think GLP-one, if you look at what's really gonna have an impact on people's lives and what will create more shareholder value, I think it's GLP-one than AI.”
  2. TED Talks Daily Can Ozempic end addiction? | Dhruv Khullar | Your Body on Tech — Dhruv Khullar “Beyond weight and diabetes, GLP-1s appear to slow or reverse fatty liver disease, chronic kidney disease, and osteoarthritis — and may reduce cardiovascular and stroke risk. Some effects appear indep…”
  3. TED Talks Daily Can Ozempic end addiction? | Dhruv Khullar | Your Body on Tech — Dhruv Khullar “When a drug is powerful enough, it becomes tempting to stop addressing the social root causes — poverty, loneliness, trauma, the food environment — that produce the problem in the first place. Khulla…”
  1. TED Talks Daily Can Ozempic end addiction? | Dhruv Khullar | Your Body on Tech — Dhruv Khullar “Mary had tried rehab, AA, and Antabuse — and failed every time. Then she enrolled in a clinical trial for Ozempic. Within weeks, the craving was gone. She stopped drinking, lost 55 pounds, ended a ba…”
  2. TED Talks Daily Can Ozempic end addiction? | Dhruv Khullar | Your Body on Tech — Dhruv Khullar “Mary lost 55 lbs in 5 months: Trial participant Mary lost 55 pounds in just 5 months on Ozempic, ultimately having to stop due to excessive weight loss, but she maintained her sobriety afterward.”
  3. TED Talks Daily Can Ozempic end addiction? | Dhruv Khullar | Your Body on Tech — Dhruv Khullar “Years before Ozempic existed, Khullar cared for a taxi driver who needed heart surgery but was too heavy to safely operate on. The surgeon said: lose weight, come back. Everyone knew that was impossi…”
  4. TED Talks Daily Can Ozempic end addiction? | Dhruv Khullar | Your Body on Tech — Dhruv Khullar “The GLP-1 landscape is about to get much more complex. Eli Lilly's retatutride hits three receptors versus the current drugs' one or two and has completed Phase 3 trials. Oral versions are coming. Wi…”
  5. The Diary Of A CEO with Steven Bartlett Anti-Aging Expert: This Reverses Gray Hair & Boosts Your Energy! — Dr. Martin Picard “Obesity is a protection mechanism against excess energy resistance. There's too much energy in the system and the system can't flow it. The mitochondria can't keep up, so to protect themselves, they …”
  6. On Purpose with Jay Shetty Dr. Chris Palmer: Your Diet Could Be Causing Anxiety, Depression & Brain Fog (6 Simple Changes to Make Today) — Dr. Chris Palmer “Decades of converging neuroscience evidence point to metabolic dysfunction — not just genes or trauma — as a root driver of conditions from depression to schizophrenia. The same biomarkers that appea…”
  7. Life Science Daily News Article GLP-1 Uptake by Country: Where Ozempic and Mounjaro Are Booming in 2026 — as of 2026-06-16
  8. HM Academy Article The GLP-1 Access Gap: Affordability by State — as of 2026-02-04
  9. The Diary Of A CEO with Steven Bartlett Dr Rachel Rubin: Women’s Sexual Health, Menopause, Hormone Replacement Therapy (HRT), and Orgasms! — Dr Rachel Rubin “25% GLP-1 users report sexual side effects: A survey of 1,000 women who had taken GLP-1 weight-loss drugs found that about 25% reported sexual side effects.”
  10. Novo Nordisk News Wegovy pill FDA approval — company announcement — as of 2025-12-22
  11. On Purpose with Jay Shetty 7 Mindset Shifts That ACTUALLY Work (Finally Change How You Think, React & Show Up) — Jay Shetty “3 degrees of social contagion: Yale social psychologist Nicholas Christakis found in a landmark longitudinal study that behaviors including happiness, obesity, and loneliness spread through social ne…”
  12. Centers for Medicare & Medicaid Services Medicare GLP-1 Bridge — as of 2026-07-01
  13. Future Market Insights Article Obesity GLP-1 Market Report — as of 2025-10-14

No sections match your search.

End of report.

Create a new report to explore a different angle.

New report All reports